 |
|
Angiotensin II Receptor BlockersA New Class of Antihypertensive Drugs
Manuel T. Velasquez, MD
Arch Fam Med. 1996;5(6):351-356.
References
Article references have been provided for searching and linking. Additional reference information may be available in the article PDF.
| |
1. Sealy JE, Laragh JH. The renin-angiotensinaldosterone system for normal regulation of blood pressure and sodium and potassium homeostasis. In: Laragh JH, Brenner BM, eds. Hypertension: Pathophysiology, Diagnosis, and Management. New York, NY: Raven Press; 1990:1287-1317.
2. Skeggs LT, Dorer FE, Kahn JR, Lentz KE, Levine M. The biochemistry of the renin-angiotensin system and its role in hypertension. Am J Med. 1976;60:737-748.
PUBMED
3. Kotchen TA, Guthrie JP Jr. Renin-angiotensinaldosterone and hypertension. Endocr Rev. 1980;1:78-99.
FREE FULL TEXT
4. Ames RP, Borkowski AJ, Sicinski AM, Laragh JH. Prolonged infusion of angiotensin II and norepinephrine and blood pressure, electrolyte balance, and aldosterone and cortical secretion in normal man and in cirrhosis with ascites. J Clin Invest. 1965;44:1171-1186.
PUBMED
5. Lohmeier TE, Cowley AW Jr. Hypertensive and renal effects of chronic low level intrarenal angiotensin infusion in the dog. Circ Res. 1979;44:154-160.
FREE FULL TEXT
6. Brown, AJ, Casals-Stenzel J, Goddord S, Lever AF, Morton JJ. Comparison of fast and slow pressor effects of angiotensin II in the conscious rat. Am J Physiol. 1981;241:H381-H388.
PUBMED
7. Diz DI, Baer PG, Nasjletti A. Angiotensin II-induced hypertension in the rat. J Clin Invest. 1983;72:466-477.
PUBMED
8. Pals DT, Masucci FD, Denning GS, Sipos F, Fessler DC. Role of the pressor action of angiotensin II in experimental hypertension. Circ Res. 1971;29:673-681.
FREE FULL TEXT
9. Miller ED, Samuels Al, Haber E, Barger AC. Inhibition of angiotensin conversion in experimental renovascular hypertension. Science. 1972;177:1108-1109.
FREE FULL TEXT
10. Gavras H, Brunner HR, Vaughan ED, Laragh JH. Angiotensin-sodium interaction in blood pressure maintenance of renal hypertensive and normotensive rats. Science. 1973;180:1369-1392.
FREE FULL TEXT
11. Buhler FR, Laragh JH, Baer L, Vaughan ED Jr, Brunner HR. Propranolol inhibition of renin secretion: a specific approach to diagnosis and treatment of renin-dependent hypertensive disease. N Engl J Med. 1972;287:1209-1214.
PUBMED
12. Brunner HR, Laragh JH. Saralasin in human hypertension: the early experience. Kidney Int. 1979;15(suppl_9):36-44.
13. Gavras H, Brunner HR, Turini GA, et al. Antihypertensive effect of the oral angiotensinconverting enzyme inhibitor SQ14225 in man. N Engl J Med. 1978;298:991-995.
ABSTRACT
14. Weber MA, Drayer JIM, Priest RT, Chen TJ. Participation of the renin system in treatment-resistant hypertension as measured by acute blockade of the angiotensin-converting enzyme. Am J Nephrol. 1982;2:6-11.
PUBMED
15. Chiu AT, Herblin WF, McCall DE, et al. Identification of angiotensin II receptor subtypes. Biochem Biophys Res Commun. 1989;165:196-203.
PUBMED
16. Timmermans PBMWM, Benfield P, Chiu AT, Herblin WF, Wong PC, Smith RD. Angiotensin II receptors and functional correlates. Am J Hypertens. 1992;5(suppl):221S-235S.
PUBMED
17. Kang J, Posner P, Sumners C. Angiotensin II type 1 (AT1) and angiotensin II type 2 (AT2) receptormediated changes in potassium currents in cultured neurons: role of intracellular calcium. FASEB J. 1992;6:A1012.
18. Bottari SP, King IN, Reichlin S, et al. The angiotensin II AT2 receptor stimulates protein tyrosine phosphatase activity and mediates particulate guanylate cyclase. Biochem Biophys Res Commun. 1992;183:206-211.
PUBMED
19. Brunner HR, Laragh JH, Baer L, et al. Essential hypertension: renin and aldosterone, heart attack and stroke. N Engl J Med. 1972;286:441-449.
PUBMED
20. Dzau V, Kopelman RJ, Barger AC, Slater EE, Haber E. Renin-specific antibody for study of cardiovascular homeostasis. Science. 1980;207:1901-1903.
21. Burton J, Cody RJ, Herd JA, Haber E. Specific inhibition of renin by an angiotensinogen analogue: studies in sodium depletion and renindependent hypertension. Proc Natl Acad Sci U S A. 1980;77:5476-5479.
FREE FULL TEXT
22. Zusman RM. Renin and non-renin-mediated antihypertensive actions of converting enzyme inhibitors. Kidney Int. 1984;969-983. 23. Okunishi H, Miyazaki M, Toda N. Evidence for a putatively new angiotensin II-generating enzyme in the vascular wall. J Hypertens. 1984;2:277-284.
PUBMED
24. Okamura T, Okunishi H, Ayajiki K, et al. Conversion of angiotensin I to angiotensin II in dog isolated renal artery: role of two different angiotensin II-generating enzymes. J Cardiovasc Pharmacol. 1990;15:353-359.
PUBMED
25. Urata H, Healy B, Stewart RW, Bumpus M, Husain A. Angiotensin II-forming pathways in normal and failing hearts. Circ Res. 1990;66:883-890.
FREE FULL TEXT
26. Brunner HR, Gavras H, Laragh JH, Keenan R. Angiotensin II-blockade in man by sar1-ala8-angiotensin II for understanding and treatment of high blood pressure. Lancet 1973;2:1045-1048.
PUBMED
27. Streeten DHP, Anderson GH Jr, Freilberg JM, Dalakos TG. Use of an angiotensin II antagonist (saralasin) in the recognition of 'angiotensinogenic' hypertension. N Engl J Med. 1975;292:657-662.
ABSTRACT
28. Case DB, Wallace JM, Keim HJ, Sealey JE, Laragh JH. Usefulness and limitations of saralasin, a partial competitive agonist of angiotensin II, for evaluating sodium and renin factors in hypertensive patients. Am J Med. 1976;60:825-836.
PUBMED
29. Anderson GH, Streeten DHP, Dalakos TG. Pressor response to 1-sar-8-ala-angiotensin II (saralasin) in hypertensive subjects. Circ Res. 1977;40:243-250.
FREE FULL TEXT
30. Baer L, Parra-Carrillo JZ, Radichevich I, Williams GS. Detection of renovascular hypertension with angiotensin II blockade. Ann Intern Med. 1977;86:257-260.
FREE FULL TEXT
31. Wilson HM, Wilson JP, Slaton PE, Foster JH, Liddle GW, Hollifield GW. Saralasin infusion in recognition of renovascular hypertension. Ann Intern Med. 1977;87:36-42.
FREE FULL TEXT
32. Furukawa Y, Kishimoto S, Nishikawa K, inventors; Takeda Chemical Industries Ltd, assignee. Hypotensive imidazole derivatives. US patent 4340598. July 20, 1982. 33. Chiu AT, McCall DE, Price WA, et al. Nonpeptide angiotensin II receptor antagonists VII: cellular and biochemical pharmacology of DuP753, an orally active antihypertensive agent. J Pharmacol Exp Ther. 1990;252:771-781.
34. Wong PC, Price WA, Chiu AT, et al. Nonpeptide angiotensin II receptor antagonists: studies with EXP 9270 and DuP 753. Hypertension. 1990;15:823-834.
FREE FULL TEXT
35. Wong PC, Price WA, Chiu AT, et al. Nonpeptide angiotensin II antagonists VIII: characterization of functional antagonism displayed DuP 753, an orally active antihypertensive agent. J Pharmacol Exp Ther. 1990;252:719-725.
FREE FULL TEXT
36. Wong PC, Price WA, Chiu AT, et al. Nonpeptide angiotensin II antagonists IX: antihypertensive activity in rats of DuP 753, an orally active antihypertensive agent. J Pharmacol Exp Ther. 1990;252:726-733.
FREE FULL TEXT
37. Burnier M, Centeno G, Grouzmann E, Walker P, Waeber B, Brunner HR. In vitro effects of DuP 753, a nonpeptide angiotensin II receptor antagonist, on human platelets and rat vascular smooth muscle cells. Am J Hypertens. 1991;4:438-443.
PUBMED
38. Smith RD, Chiu AT, Wong PC, Herblin WF, Timmermans PBMWM. Pharmacology of nonpeptide angiotensin II receptor antagonists. Annu Rev Pharmacol Toxicol. 1992;32:135-165.
PUBMED
39. Wong PC, Price WA, Chiu AT, et al. Hypotensive action of DUP 753, an angiotensin II antagonist, in spontaneously hypertensive rats. Hypertension. 1990;15:459-468.
FREE FULL TEXT
40. Fenoy FJ, Milicic I, Smith RD, Wong PC, Timmermans PBMWM, Roman R. Effects of DuP 753 on renal function of normotensive and spontaneously hypertensive rats. Am J Hypertens. 1991;4(suppl):321S-326S.
PUBMED
41. Bovee KC, Wong PC, Timmermans PBMWM, Thoolen MJMC. Effects of nonpeptide angiotensin II receptor antagonist DuP 753 on blood pressure and renal function in spontaneously hypertensive PH dogs. Am J Hypertens. 1991;4(suppl):327S-333S.
PUBMED
42. Wong PC, Price WA, Chiu AT, et al. Nonpeptide angiotensin II antagonists XI, pharmacology of EXP3174: an active metabolite of DuP 753, an orally active antihypertensive agent. J Pharmacol Exp Ther. 1990;252:211-217.
43. Criscione L, De Gasparo M, Buhlmayer P, Whitebread S, Ramjoue HPR, Wood J. Pharmacological profile of valsartan: a potent, orally active, nonpeptide antagonist of the AT1 receptor subtype. Br J Pharmacol. 1993;110:761-771.
PUBMED
44. Lee JY, Brune ME, Warner RB. Characterization of antihypertensive activity of ABBOTT-81988 a nonpeptide angiotensin II antagonist in the renal hypertensive rat. J Pharmacol Exp Ther. 1994;268:427-433.
FREE FULL TEXT
45. Lee JU, Warner RB, Brune ME, et al. Cardiovascular effects of orally administered ABBOTT-81988, an angiotensin II antagonist, in conscious spontaneously hypertensive rats. Am J Hypertens. 1994;7:975-983.
PUBMED
46. Christen Y, Waeber B, Nussberger J, et al. Oral administration of DuP 753, a specific angiotensin II receptor antagonist, to normal male volunteers: inhibition of pressor response to exogenous angiotensin I and II. Circulation. 1991;83:1333-1342.
FREE FULL TEXT
47. Goldberg MR, Tanaka W, Barchowsky A, et al. Effects of losartan on blood pressure, plasma renin activity, and angiotensin II in volunteers. Hypertension. 1993;21:704-713.
FREE FULL TEXT
48. Sissmann J, Bouroudian M, Armagnac C, Donazollo Y, Latreille M, Panis R. Angiotensin II blockade in healthy volunteers: tolerability and impact on renin angiotensin system components of single and repeated doses of a new angiotensin II receptor antagonist SR 47436 (BMS 186295). J Hypertens. 1994;12(suppl 3):508.
49. Burnier M, Rutschmann B, Nussberger J, et al. Salt-dependent effects of an angiotensin II antagonist in healthy subjects. Hypertension. 1993;22:339-347.
FREE FULL TEXT
50. Nelson E, Arcuri K, Ikeda L, Snavely D, Sweet C. Efficacy and safety of losartan in patients with essential hypertension. Am J Hypertens. 1992;5:19A.
51. Tsunoda K, Abe K, Hagino T, et al. Hypotensive effect of losartan, a nonpeptide angiotensin II receptor antagonist, in essential hypertension. Am J Hypertens. 1993;6:28-32.
PUBMED
52. Grossman E, Peleg E, Carroll J, Shamiss J, Rosenthal T. Hemodynamic and humoral effects of the angiotensin II antagonist losartan in essential hypertension. Am J Hypertens. 1994;7:1041-1044.
PUBMED
53. Goldberg MR, Bradstreet TE, McWilliams EJ, et al. Biochemical effects of losartan, a nonpeptide angiotensin II receptor antagonist, on the reninangiotensin aldosterone system in hypertensive patients. Hypertension. 1995;25:37-46.
FREE FULL TEXT
54. Dahlöf B, Keller SE, Makris L, et al. Efficacy and tolerability of losartan potassium and atenolol in patients with mild to moderate essential hypertension. Am J Hypertens. 1995;8:578-583.
PUBMED
55. Weber MA, Byyny RL, Pratt JH, et al. Blood pressure effects of the angiotensin II receptor blocker, losartan. Arch Intern Med. 1995;155:405-411.
FREE FULL TEXT
56. Soffer BA, Wright JT Jr, Pratt JH, Wiens B, Goldberg Al, Sweet CS. Effects of losartan on a background of hydrochlorothiazide in patients with hypertension. Hypertension. 1995;26:112-117.
FREE FULL TEXT
57. Shaw H, Snavely D, Shahnaz S. Safety and efficacy of losartan (DuP 753, MK-945) in hypertensive patients with renal impairment. J Am Soc Nephrol. 1994;5:567.
58. van den Meiracker AH, Admiraal PJJ, Janssen JA, et al. Hemodynamic and biochemical effects of the AT, receptor antagonist irbesartan in hypertension. Hypertension. 1995;25:22-29.
FREE FULL TEXT
59. Lacourciére Y, Brunner H, Irwin R, et al. Effect of modulators of the renin—angiotensin— aldosterone system on cough. J Hypertens. 1994;12:1387-1393.
PUBMED
60. Remuzzi A, Perico N, Amuchastegui CE, et al. Short- and long-term effect of angiotensin II receptor blockade in rats with experimental diabetes. J Am Soc Nephrol. 1993;4:40-49.
ABSTRACT
|
